INFU vs USPH
INFU: InfuSystem is a specialized provider of durable medical equipment and managed healthcare services that enables the seamless transition of oncology and other infusion therapies from clinical settings to the home. USPH: A roll-up platform consolidating fragmented outpatient physical therapy and occupational therapy clinics while building a B2B workplace injury prevention and ergonomics business serving Fortune 500 employers.
Side-by-side fundamentals
| Metric | INFU | USPH | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $9.36 | $76.64 | |
| Market cap as of 2026-08-01 | $184M | $1.2B | |
| P/E as of 2026-08-01 | 23.28 | 33.76 | INFU lower |
| PEG as of 2026-08-01 | 0.16 | 11.21 | INFU lower |
| Net margin as of 2026-08-01 | +5.6% | +4.4% | INFU higher |
| Gross margin as of 2026-08-01 | +56.8% | +19.0% | INFU higher |
| Operating margin as of 2026-08-01 | +9.1% | +10.0% | USPH higher |
| ROE as of 2026-08-01 | +14.0% | +7.1% | INFU higher |
| ROA as of 2026-08-01 | +7.9% | +2.9% | INFU higher |
| Debt / equity as of 2026-08-01 | 0.33 | 0.44 | INFU lower |
| Revenue growth (YoY) as of 2026-08-01 | +3.5% | +13.7% | USPH higher |
| Revenue CAGR (3y) SEC XBRL | +9.3% | +12.2% | USPH higher |
| Dividend yield as of 2026-08-01 | n/a | +2.3% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-08-01 | 1.49 | 1.12 | |
| 1-year return as of 2026-07-27 close | +55.7% | +3.2% | INFU higher |
Fundamentals: market data, as of 2026-08-01. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.